Richter Gedeon Vegyeszeti Gyar Rt

Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt.

Lajos Szabo

Csaba Szantay

Gyorgy Kalaus

Laszlo Szporny

Egon Karpati

Tibor Keve

Lajos Dancsi

Katalin Honty

Ferenc Drexler

Janos Kreidl

Istvan Tibor Toth

Sandor Eckhardt

Janos Sapi

Janos Sugar

Sandor Virag

Laszlo Czibula

Andras Nemes

Maria Farkas Nee Kirjak

Gyorgy Visky

Eszter Dezseri

Tibor Acs

Erzsebet Kanyo

Bela Kiss

Agoston David

Gyorgy Fekete

Laszlo Toke

Tibor Cs

Zsuzsa Kneffel

Eva Ivan

Eva Palosi

Sandor Gorog

Elemer Ezer

Karola Jovanovics

Csaba Lorincz

Arpad Kiraly

Lilla Forgach

Maria Zajer Nee Balazs

Bela Rosdy

Gyongyver Kiraly Nee Soos

Sandor Kerpel-Fronius

Zsuzsa Somfai

Bela Szarvady

Ivan Hindi

Gyorgy Hajos

Gabor Kovacs

Bela Stefko

Erzsebet Lapis

Gyula Sebestyen

Istvan Laszlovszky

Janos Galambos

Zsolt Szombathelyi

Aniko Gere

Katalin Csomor

Lajos Kovacs

Katalin Nogradi

Jozsef Gaal

Jeno Marton

Lilla Forgacs

Csaba Kuthi

Gyorgy Somogyi

Judit M Meszaros Nee Brill

Laszlo Harsing

Gyorgy Dobo

Zsuzsanna Relle Nee Somfa

Maria Farkas Nee Kirlyak

Mari Zajer Nee Balazs

Ferenc Vezekenyi

Zsuzsanna Gyulai

Zsuzsa Somjai

Csaba Szantai

Szilveszter Vizi

Maria Gazdac

Gyoorgy Kalaus

Zsuzsanna Relle Nee Somfai

Krisztina Mihalyfi

Laszlo Cibula

The invention relates to novel racemic or optically active berban derivatives of the formula (I) ##STR1## wherein R.sup.1 and R.sup.2 represent independently from the other a hydroxyl, straight or branched chain alkoxy group 1 to 6 carbon atoms or R.sup.1 and R.sup.2 together represent a C.sub.1-3 alkylenedioxy group;

Berban derivatives as .alpha..sub.2 -adrenergic antagonists

The invention relates to the new (-)-1.beta.-ethyl-1.alpha.-hydroxymethyl-1,2, 3,4,6,7,12,12b.alpha.-octa-hydroindolo[2,3-a] quinolizine of the formula (I) ##STR1## and acid addition salts thereof. According to another aspect of the invention there is provided a process for the preparation of the compound of formula (I) and acid addition salts thereof by resolution of the corresponding racemic compound and optionally by subsequent hydrolysis and/or salt formation. The compound of formula (I) shows a remarkable peripheral vasodilating and antihypoxial activity. Pharmaceutical compositions comprising it as active ingredient are also within the scope of the invention.

(-)-1.beta.-ethyl-1.alpha.-hydroxymethyl-1,2,3,4,6,7,12,

The invention relates to novel bis-indole derivatives of the general formula (I) ##STR1## wherein R.sub.1 stands for a hydrogen atom or an acetyl group;

Bis-indole derivatives and pharmaceutical compositions containing them

The invention relates to novel furfuryl derivatives of the general formula (I), ##STR1## wherein R.sub.1 stands for a hydrogen atom or an acetyl group,

Furfuryl derivatives of vinblastine-type bis-indoles, and pharmaceutical

The invention relates to novel nitro derivatives of the general formula (I) ##STR1## wherein R.sub.1 stands for a methyl or a formyl group;

Nitro derivatives of vinblastine-type bisindoles, and pharmaceutical

The invention relates to new eburnane derivatives of the formula (I) ##STR1## wherein R.sup.1 is alkyl having from 1 to 6 carbon atoms, and acid addition salts thereof. The invention further relates to a process for the preparation of these compounds and pharmaceutical compositions containing them. Compounds of formula (I) show remarkable CNS-activity and are useful intermediates in the preparation of other, pharmaceutically active compounds.

Eburnane derivatives, process for their preparation and pharmaceutical

A process is disclosed for the preparation of dimeric alkaloids of formula (II) ##STR1## wherein R stands for methyl or formyl, as well as acid addition salts thereof which comprises oxidizing the vinblastine of formula (III) ##STR2## with chromium (VI) oxide or bichromate or chromic acid alcohol ester in an inert solvent, converting the compound of formula (II), wherein R stands for methyl, so obtained to the acid addition salt and optionally further oxidizing the acid addition salt obtained with an oxidizing agent as defined above and optionally converting the compound of formula (II), wherein R stands for formyl, so obtained to the acid addition salt.

Process for the preparation of dimeric alkaloids

The invention relates to racemic or optically active eburnane derivatives of the formula (I), ##STR1## wherein R represents an alkyl group having 1 to 6 carbon atoms,

The invention relates to optically active or racemic eburnane-oxime ethers of the formulae (Ia) and/or ##STR1## wherein R represents an alkyl group having 1 or 2 carbon atoms,

Eburnane oxime ethers

The invention relates to new cytostatic compound, process for their preparation and pharmaceutical compositions containing them. More particularly, there are provided new compounds of the general formula ##STR1## in which R.sup.4 is .beta.-hydroxyl and

N-Desmethyl-N-(allyloxymethyl)-vinblastine and antileukemic and

The invention relates to racemic or optically active E-homo-eburnane derivatives of the formula /I/, ##STR1## wherein R.sup.1 and R.sup.2 independently represent an alkyl group having 1 to 6 carbon atoms,

E-Homo-eburnane derivatives, process for their preparation, and

A process is disclosed for the preparation of racemic cis or trans apovincaminic acid esters of the formula (I) ##STR1## and the corresponding optically active derivatives of the formulae (Ia) ##STR2## wherein R.sup.1 and R.sup.2 are identical or different alkyl groups having 1 to 6 carbon atoms. Apovincaminic acid alkyl esters are well-known vasodilating compounds.

Apovincaminic acid esters

The invention relates to a new process for the preparation of eburnamonine derivatives of the general Formula I ##STR1## (wherein R.sup.1 is an alkyl group having 1-6 carbon atoms) and optical and geometrical isomers thereof which comprises reacting a hydroxyimino-octahydro-indolo[2,3-a]quinolizine derivative of the general Formula II ##STR2## (wherein R.sup.1 is as stated above and R.sup.2 stands for an alkyl group having 1-6 carbon atoms being identical with or different from R.sup.1, or a hydrogen atom) or an acid addition salt thereof in an organic protic solvent or solvent mixture with an inorganic base, optionally under the addition of water or an aqueous mineral acid, at a temperature between 60.degree. C. and 200.degree. C. The compounds of the present invention are known drugs having blood pressure decreasing and cerebral vasodilatatory effect. The advantage of the process of the present invention is that it is readily feasible on industrial scale too, provides isomer-free pure products with high yield and requires the use of readily available simple starting materials.

Process for the preparation of eburnamonine derivatives

The invention relates to a new process for the preparation of apovincaminic acid esters. More particularly, the invention concerns a process for preparing racemic and optionally active vincaminic acid esters of the formula (I) ##STR1## in which R.sup.1 and R.sup.2 independently stand for alkyl having from one to 6 carbon atoms, and 14-epimers thereof. According to the invention an octahydroindolo[2,3-a]quinolizine-oxime ester of the formula (II) ##STR2## in which R.sup.1 and R.sup.2 have the same meaning as defined above, is reacted with an aqueous solution of sulfurous acid or a salt thereof at a temperature of 80.degree. to 110.degree. C. and the 14-epimeric mixture obtained is epimerized or separated in a known manner and if desired, the racemic vincaminic acid esters are resolved. The valuable, pharmaceutically active compounds of the formula (I) can be prepared according to the invention in a considerably improved yield and the undesired side reactions can be suppressed and/or the by-products can easily be converted into other pharmaceutically active materials.

Process for the preparation of vincaminic acid esters

New salts of the formula XIIIa and XIIIb are disclosed ##STR1## wherein R.sup.2, R.sup.3 and R.sup.5 are each C.sub.1 to C.sub.6 alkyl and A.sup.- is an anion of a pharmaceutically acceptable acid. Furthermore new compounds of the formula XIVa and XIVb are disclosed: ##STR2## wherein R.sup.2 and R.sup.3 are as defined above. The new salts and compounds are intermediates in the preparation of 10-bromo-vincaminic acid esters. In addition the new salts and compounds have the ability to increase blood circulation and to decrease blood flow resistance in an animal subject while at the same time maintaining a steady pulse rate and blood pressure.

9-Bromo-hexahydro- and octahydro-indolo[2,3 a]quinolizines and use for

Growing community of inventors

Budapest, Hungary

Lajos Szabo